Background: Cancer is one of the leading diseases responsible for deaths in the society. According to
the American cancer society, there will be 95,270 new cases of colon cancer in the U.S. in 2016. When a normal
cell turns cancerous they develop into tumours, which produce various pro-inflammatory and inflammatory
cytokines and chemokines that attract leukocytes to the site of growth. The main aim of this paper is to introduce
readers about the increased number of cancer patient, effects of cancer and need of research on same.
Methods: The target molecules were prepared by reacting pyrazolealdehyde with appropriate aromatic ketone
by using polyethylene glycol (PEG-300) as green solvent and catalyst to yield chalcone. Furthermore, the reaction
of chalcones with thiosemicabazide yields asymmetric 1-thiocarbamoyl pyrazoles. All the newly synthesized
compounds were in vitro screened for their anticancer activities against Colon SW-620 by employing the
sulforhodamine B (SRB) assay method. Also all the synthesized compounds tested for in vitro antioxidant and
anti-inflammatory activity by using known literature methods.
Results: Preliminary in vitro evaluation indicated that most of the compounds 4c, 4d and 4e possess distinct
cytotoxicity profile against Colon SW-620 cell line compared to standard drug adriamycin. All the tested compounds
showed good to excellent antioxidant activity against one or more reactive (H2O2, DPPH, SOR and NO)
radical scavenging species. Additionally, all the synthesized compounds were screened for their in vitro antiinflammatory
activity. Compounds 4a, 4b and 4e shows potent anti-inflammatory activity as compared to diclofenac
sodium as a standard reference.
Conclusion: New anti- Colon SW-620 cancer agents are the need of time, we trust that 1-thiocarbamoyl pyrazole
derivatives 4c, 4d and 4e constitute an interesting template for the evaluation of new anticancer agent also
antioxidant and anti-inflammatory work may provide an interesting insight for further development.